📰 Valency Communications News
Page 5 - Valency Communications News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Valency Communications. Real-time updates on events, politics, business and more.
April 15, 2022
15.04.2022 - Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, today announced that its Annual Report for 2021 is now available on the Company’s corporate ...
April 14, 2022
Immunicum AB ("Immunicum" publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, today announced that the company will participate
April 14, 2022
Investegate announcements from Immunicum AB, Immunicum AB: Immunicum to Participate in the New Cancer Research Consortium Oncode-PACT
April 14, 2022
Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established...
April 8, 2022
08.04.2022 - Press Release Stockholm, Sweden, April 8, 2022 NOTICE OF ANNUAL GENERAL MEETING IN IMMUNICUM AB (PUBL) The shareholders of Immunicum AB (publ) (the “Company”), reg. no 556629-1786, are hereby invited to the Annual General ...
February 18, 2022
OCTOBER-DECEMBER IN SUMMARY Net sales for the period amounted to KSEK - (-).Result for the period amounted to KSEK -32,844 (-47,880).Earnings and diluted earnings per share totaled SEK -0.16 (-0.58).Immunicum
February 18, 2022
OCTOBER-DECEMBER IN SUMMARY Net sales for the period amounted to KSEK - (-).Result for the period amounted to KSEK -32,844 (-47,880).Earnings and diluted earnings per share totaled SEK -0.16 (-0.58).Immunicum
February 18, 2022
Investegate announcements from Immunicum AB, Correction: Immunicum AB: Immunicum AB (publ) Announces Q4 and Year-End Results 2021
February 17, 2022
OCTOBER-DECEMBER IN SUMMARY Net sales for the period amounted to KSEK - (-).Result for the period amounted to KSEK -32,844 (-47,880).Earnings and diluted earnings per share totaled SEK -0.16 (-0.58).Immunicum
February 10, 2022
10.02.2022 - Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on the prevention of cancer recurrence and addressing hard-to-treat tumors, will publish its financial results for the fourth quarter and full year ended December 31, 2021 ...